HealthdirectFree Australian health advice you can count on.

( ARTG ) This product is accepted for registration as 'currently supplied' at the time of commencement of the Act.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ New indications were approved as specified in the letter of 16 June 1992 from Dr L. Hunt. Indications: as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. Extended indications as at 15 October 1993: For induction and/or maintenance of remission in the nephrotic syndrome. Cyclosporin is not a first-line agent. Its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired . Indications as at 11 February 1994 from Dr J. McGinness: 1. As an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. 2. For induction and/or maintenance of remission in the nephrotic syndrome. Cyclosporin is not a first-line agent. Its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired. 3. For the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. 4. In patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with the quality of life.